NEWS |
| 05.12.2008 |
Akorn Reports First Quarter 2008 Financial Results |
 |
| 05.02.2008 |
Akorn, Inc. Announces First Quarter 2008 Earnings Release and Conference Call Information |
|
| 04.30.2008 |
Akorn, Inc. to Present at Bank of America 2008 Health Care Conference |
|
| 04.29.2008 |
Akorn, Inc. to Present at Deutsche Bank Securities 33rd Annual Health Care Conference |
|
| 04.24.2008 |
Akorn-Strides, LLC Announces FDA Approvals for Ondansetron Injection USP, 4 mg/2mL Single Dose Vials and Ondansetron Injection USP, 40 mg/20mL Multiple Dose Vials |
|
| 04.18.2008 |
Akorn, Inc. Announces FDA Approval of Diclofenac Sodium Ophthalmic Solution 0.1% |
|
| 04.16.2008 |
Akorn, Inc. Announces FDA Approval of Ofloxacin Ophthalmic Solution USP, 0.3% |
|
| 04.03.2008 |
Akorn, Inc. Signs Supply Agreement with Fresenius Kabi for Premix Product |
|
| 03.24.2008 |
Akorn Enters into a Commercial Manufacturing Supply Agreement for Three OTC Products |
|
| 03.19.2008 |
Akorn-Strides, LLC Announces FDA Approval for Fosphenytoin Sodium Injection USP, 100 mg/2mL and 500 mg/10mL |
|
| 03.11.2008 |
Akorn Reports Fourth Quarter and Full Year 2007
Financial Results; Provides 2008 Outlook |
|
| 03.07.2008 |
Akorn, Inc. Announces Year-End 2007 Earnings Release and
Conference Call Information |
|
| 02.21.2008 |
Akorn Inc. and CSL Biotherapies Sign a Specialty Distributor Agreement for Afluria(R) (Flu Vaccine) |
|
| 02.14.2008 |
Akorn Enters into a Manufacturing and Supply Agreement for the Contract Manufacture of an Ophthalmic Solution |
|
| 02.12.2008 |
Akorn, Inc. to Present at Credit Suisse Specialty Pharmaceuticals Health Care Conference |
|
| 01.30.2008 |
Akorn, Inc. Announces FDA Approval of Calcitriol Injection, 1 mcg/mL and 2 mcg/mL |
|
| 12.21.2007 |
Akorn, Inc. Announces FDA Inspection Results |
|
| 12.05.2007 |
Akorn, Inc. Announces First ANDA Submission For Serum Institute of India, Ltd. |
|
| 11.27.2007 |
Akorn, Inc. and Cipla, Ltd. Announce the Signing of an Exclusive Manufacturing and Supply Agreement for an Inhalation Drug Product |
|
| 11.26.2007 |
Akorn, Inc. Announces FDA Approval for Unit Dose Preservative Free Tetanus Diphtheria Vaccine |
|
| 11.01.2007 |
Akorn Reports Third Quarter 2007 Financial Results |
|
| 10.31.2007 |
Akorn, Inc. to Present at CIBC World Markets 18th Annual Healthcare Conference |
|
| 10.29.2007 |
Akorn, Inc. Announces Exclusive Vaccine Partnership Conference Call Information |
|
| 10.29.2007 |
Akorn, Inc. Enters into Exclusive Vaccine Partnership with Serum Institute of India, Ltd. |
|
| 10.25.2007 |
Akorn, Inc. Announces New Center for Excellence |
|
| 10.18.2007 |
Akorn, Inc. Announces Third Quarter 2007 Earnings Release and Conference Call Information |
|
| 10.11.2007 |
Akorn, Inc. Signs an Exclusive Licensing, Development and Supply Agreement with Sofgen Pharmaceuticals |
|
| 09.26.2007 |
Akorn, Inc. Announces Release of IC-Green(TM) |
|
| 09.07.2007 |
Akorn Announces Submission of an ANDA Drug Product Developed Jointly with Sofgen Pharmaceuticals |
|
| 09.05.2007 |
Akorn, Inc. Launches Tetanus Diphtheria Vaccine |
|
| 07.30.2007 |
Akorn Reports Second Quarter 2007 Financial Results |
|
| 07.30.2007 |
Akorn Announces Development and Supply Agreement with Hyaluron For Two Injectable ANDA Suspension Drug Products |
|
| 07.27.2007 |
Akorn, Inc. Announces FDA Approval of Ketotifen Fumarate Ophthalmic Solution, 0.025% |
|
| 07.23.2007 |
Akorn, Inc. Announces Second Quarter 2007 Earnings Release and Conference Call Information |
|
| 07.19.2007 |
Akorn, Inc. and Cipla, Ltd. Announce the Signing of an Exclusive Drug Development and Supply Agreement for an Injectable ANDA Drug Product for the Prevention of Organ Transplant Rejection |
|
| 07.17.2007 |
Akorn-Strides, LLC Announces its First ANDA Approval For Ketorolac Tromethamine Injection USP, 15 mg/mL and 30 mg/mL |
|
| 07.17.2007 |
Akorn, Inc. Signs Exclusive Development and Supply Agreement with Haemonetics Corporation for Three Premix Products |
|
| 06.29.2007 |
Akorn, Inc. Announces the New Drug Application (NDA) Filing for Akten(R) |
|
| 06.21.2007 |
Akorn, Inc. and Cipla, Ltd. Announce the Signing of an Exclusive Drug Development and Supply Agreement for an Oral ANDA Drug Product for the Prevention of Organ Transplant Rejection |
|
| 06.08.2007 |
Akorn, Inc. and Natco Pharma Limited add Two Injectable Drug Products To API Supply and Margin Sharing Agreement |
|
| 05.22.2007 |
Akorn Inc. Names Douglas R. Pinnell As Vice President, Vaccine Sales |
|
| 05.18.2007 |
Akorn, Inc. to Present at Bank of America 2007 Health Care Conference |
|
| 05.15.2007 |
Akorn, Inc. to Present at Friedman, Billings, Ramsey 2007 Growth Conference |
|
| 05.14.2007 |
Akorn Joins NASDAQ Biotechnology Index |
|
| 05.07.2007 |
Akorn, Inc. Announces First Quarter 2007 Earnings Release and Conference Call Information |
|
| 05.01.2007 |
Akorn, Inc. Announces First Quarter 2007 Earnings Release and Conference Call Information |
|
| 04.18.2007 |
Akorn, Inc. to Present at UBS Global Generic and Specialty Pharmaceuticals Conference |
|
| 04.05.2007 |
Akorn, Inc. Names Shawn L. Silvestri, Ph.D. As Vice President, New Product Development |
|
| 04.04.2007 |
Akorn, Inc. to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference |
|
| 03.27.2007 |
Akorn, Inc. Signs Exclusive Distribution Agreement With Massachusetts Biologic Laboratories For Tetanus Diphtheria Vaccine |
|
| 03.05.2007 |
Akorn Reports Record Net Revenue of $71.2 Million in 2006: A 60% Increase Versus 2005 |
|
| 02.26.2007 |
Akorn, Inc. Announces Year-End 2006 Earnings Release and Conference Call Information |
|
| 02.21.2007 |
Akorn, Inc. to Present at Credit Suisse Health Care Conference |
|
| 01.30.2007 |
Akorn, Inc. Signs an Exclusive Supply Agreement For Hydase(TM) (Hyaluronidase Injection, USP) 150 Units/mL, an NDA Product |
|
| 01.25.2007 |
Akorn, Inc. Announces Move to Nasdaq Global Market |
|
| 01.23.2007 |
Akorn, Inc. Announces Positive Phase III Pivotal Trial Results for Akten(R) |
|
| 01.09.2007 |
Akorn, Inc. Signs Exclusive Definitive Agreement For the Development and Supply of Three Ophthalmic ANDA Drug Products |
|
| 12.06.2006 |
Akorn, Inc. and Strides Arcolab Limited Agree to Expand the Akorn-Strides, LLC Joint Venture Product Pipeline to Twenty-Nine ANDA's |
|
| 11.30.2006 |
Akorn, Inc. Announces Tentative Approval of Diclofenac Sodium Ophthalmic Solution 0.1% |
|
| 11.27.2006 |
Akorn, Inc. Expands its Definitive Purchase and Supply Agreement With Natco Pharma Limited to Include One Additional Oral Drug Product
|
|
| 11.13.2006 |
Akorn, Inc. and FDC Limited Sign Exclusive Development and Supply Agreement for Two Ophthalmic Suspension Drug Products |
|
| 11.08.2006 |
Akorn, Inc. and Serum Institute of India, Ltd. Announce the Signing of a Definitive Development and Exclusive Distribution Agreement for Rabies Monoclonal Antibody
|
|
| 11.02.2006 |
Akorn, Inc. and Natco Pharma Limited Add Two Injectable Drug Products To API Supply and Margin Sharing Agreement |
|
| 10.30.2006 |
Akorn, Inc. Reports Third Quarter 2006 Revenues of $14.5 million and 41% Gross Margin
|
|
| 10.16.2006 |
Akorn, Inc. Announces Third Quarter 2006 Earnings Release and Conference Call Information |
|
| 09.18.2006 |
Akorn Announces $3.5 Million Purchase Order For Calcium-DTPA and Zinc-DTPA
|
|
| 09.08.2006 |
Akorn, Inc. Announces Equity Investment by Serum Institute of India, Ltd. |
|
| 08.31.2006 |
Akorn, Inc. and GeneraMedix Inc. Sign Commercial Manufacturing Supply Agreement |
|
| 08.25.2006 |
Akorn-Strides, LLC Announces Tenth ANDA Submission |
|
| 08.17.2006 |
Akorn, Inc. Announces First ANDA Submission for FDC Limited |
|
| 08.10.2006 |
Akorn, Inc. Signs a Definitive Exclusive Development and Supply Agreement with Sofgen to Develop and Commercialize an ANDA Drug Product |
|
| 08.07.2006 |
Akorn, Inc. Signs Definitive Commercial Manufacturing Supply Agreement with Advanced Vision Research, Inc. |
|
| 08.02.2006 |
Akorn, Inc. to Present at Bank of America Health Care Conference |
|
| 08.01.2006 |
Akorn, Inc. Receives U.S. IND Clearance for the Clinical Development of AK-1015, an NDA Drug Product for Ocular Anesthesia |
|
| 07.26.2006 |
Akorn, Inc. Reports Second Quarter 2006 Revenues Of $12.5 Million And 40% Gross Margin |
|
| 07.24.2006 |
Akorn, Inc. Announces Product Approval For Diltiazem Hydrochloride Injection |
|
| 07.20.2006 |
Akorn, Inc. Announces Second Quarter Earnings Release And Conference Call Information |
|
| 06.07.2006 |
Akorn, Inc. Announces Supplemental New Drug Application Approval for Sufenta(R) |
|
| 06.06.2006 |
Akorn, Inc. Announces Contract Manufacturing Supply Agreement with Advanced Vision Research, Inc. |
|
| 06.06.2006 |
Akorn, Inc. to Present at FTN Midwest Health Care Conference |
|
| 05.24.2006 |
Akorn, Inc. Announces Product Approval for Orphenadrine Citrate Injection |
|
| 05.24.2006 |
Akorn, Inc. to Present at Friedman, Billings, Ramsey Growth Investor Conference |
|
| 05.10.2006 |
Akorn, Inc. to Present at Bank of America Health Care Conference |
|
| 05.09.2006 |
Akorn, Inc. Announces Contract Manufacturing Supply Agreement with X-Gen Pharmaceuticals |
|
| 05.02.2006 |
Akorn, Inc. Signs a Definitive Agreement with Fidia Farmaceutici, S.p.A. To Develop Four ANDA Drug Products for Commercialization |
|
| 05.01.2006 |
Akorn, Inc. Reports First Quarter 2006 Revenues of $30 million, 40% Gross Margin and Diluted Earnings per Share of $0.04 |
|
| 04.24.2006 |
Akorn, Inc. Announces Supplemental New Drug Application Approval for Inapsine (R) |
|
| 04.21.2006 |
Akorn, Inc. and Natco Pharma Limited Sign a Definitive API Supply and Margin Sharing Agreement to Develop and Market Two Injectable Drug Products |
|
| 04.21.2006 |
Akorn-Strides, LLC Announces First ANDA Submission for a Lyophilized Injectable Drug Product |
|
| 04.20.2006 |
Akorn, Inc. Revises Time of Q1'06 Earnings Release |
|
| 04.20.2006 |
Akorn, Inc. Announces First Quarter Earnings Release And Conference Call Information |
|
| 04.19.2006 |
Akorn, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference |
|
| 04.03.2006 |
Akorn-Strides, LLC Announces First ANDA Submission |
|
| 03.31.2006 |
Akorn Announces Conversion of Two Convertible Promissory Notes to Common Stock |
|
| 03.28.2006 |
Akorn, Inc. Signs a Definitive Purchase and Supply Agreement With Natco Pharma Limited to Market Two Oral Drug Products |
|
| 03.20.2006 |
Akorn, Inc. Announces First Post-Inspection Product Approval for Decatur Manufacturing Facility |
|
| 03.08.2006 |
Akorn, Inc. Completes $19.4 Million Private Placement of Common Stock |
|
| 03.07.2006 |
Akorn, Inc. and Cipla, Ltd. Announce the Signing of an Exclusive Drug Manufacturing and Supply Agreement For an Oral Anti-Infective ANDA Drug Product
|
|
| 03.06.2006 |
Akorn, Inc. Reports Year End 2005 Results and Provides Outlook for 2006 |
|
| 03.01.2006 |
Akorn, Inc. Announces Additional $4.3 Million in Private Placement of Common Stock
|
|
| 03.01.2006 |
Akorn, Inc. Announces $15.1 Million Private Placement of Common Stock |
|
| 02.27.2006 |
AKORN, INC. TO ANNOUNCE RESULTS FOR THE FOURTH QUARTER AND
YEAR ENDED DECEMBER 31, 2005 AND PROVIDE UPDATED 2006 OUTLOOK
|
|
| 02.16.2006 |
Akorn, Inc. Names David White, Ph.D, Vice-President, New Product Development |
|
| 02.13.2006 |
Akorn Announces Funding Approval For Calcium-DTPA and Zinc-DTPA |
|
| 01.13.2006 |
Akorn Retires Series A Preferred Stock |
|
| 12.30.2005 |
Akorn Announces $21.5 Million Award For Calcium-DTPA and Zinc-DTPA |
|
| 12.19.2005 |
Akorn, Inc. Signs Letter of Intent with Natco Pharma Limited To Develop and Supply Two Oral Tablet Drug Products |
|
| 12.14.2005 |
Akorn, Inc. Signs Letter of Intent with Azad Pharma AG to Develop and Supply Three ANDA Injectable Drug Products |
|
| 12.14.2005 |
Akorn, Inc. Announces FDA Inspection Results |
|
| 11.08.2005 |
Akorn, Inc. Signs a Letter of Intent with Cipla, Ltd. to Develop and Supply an Oral Anti-Infective ANDA Drug Product |
|
| 11.07.2005 |
Akorn, Inc. Reports Third Quarter 2005 Financial Results |
|
| 10.24.2005 |
Akorn, Inc. to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference |
|
| 10.13.2005 |
Akorn, Inc. Signs Letter of Intent with Fidia Farmaceutici, S.p.A. To Develop Four ANDA Drug Products for Commercialization |
|
| 10.10.2005 |
Akorn, Inc. Announces Receipt of Request for Proposal (RFP) for Calcium-DTPA and Zinc-DTPA |
|
| 09.30.2005 |
Akorn, Inc. Renews Credit Agreement With LaSalle Bank National Association |
|
| 09.15.2005 |
Akorn, Inc. Updates Status of Calcium - DTPA and Zinc-DTPA Strategic National Stockpile Order |
|
| 08.15.2005 |
Akorn, Inc. To Develop Unique Ophthalmic Formulation for a Therapeutic Product |
|
| 08.01.2005 |
Akorn, Inc. Reports Net Sales of $12.6 million in Second Quarter 2005 with Gross Margin of 39% and $1.1 million Consolidated EBITDA |
|
| 07.11.2005 |
Akorn Inc. Joins New Russell Microcap Index |
|
| 05.25.2005 |
Akorn Inc. Opens First International Office, Names Vandana J. Sonavaria, Ph.D. Director, International Compliance and Regulatory Affairs |
|
| 05.17.2005 |
Akorn, Inc. Names Russell A. Gall, Vice-President and General Manager, Decatur Operations |
|
| 05.16.2005 |
Akorn Retires NeoPharm Promissory Note |
|
| 05.06.2005 |
Akorn, Inc. Reports Net Sales of $10.2 Million in 2005 First Quarter With Gross Margin of 33%, Breakeven EBITDA and Positive Cash Flow |
|
| 05.03.2005 |
Akorn Launches Two New Ophthalmic Drug Products |
|
| 04.25.2005 |
Akorn, Inc. Names Mark M. Silverberg as Vice President, Global Quality and Regulatory Compliance |
|
| 04.13.2005 |
Akorn, Inc. Announces Purchase and Supply Agreement |
|
| 02.28.2005 |
Akorn, Inc. Reports Net Sales of $12.6 Million in 2004 Fourth Quarter with Gross Margin of 33% and EBITDA of $1.0 Million |
|
| 02.28.2005 |
Watch the Video: Akorn, Inc. Rings the Opening Bell at AMEX |
|
| 02.23.2005 |
Akorn, Inc. to Present at Leerink Swann Inaugural Healthcare Conference |
|
| 02.17.2005 |
Akorn, Inc. Enters into an Agreement to License a Patent from the University of Texas M.D. Anderson Cancer Center |
|
| 01.10.2005 |
Akorn and Apotex Sign Product Supply Agreement |
|
| 11.18.2004 |
Akorn, Inc. Announces American Stock Exchange Listing Approval |
|
| 11.16.2004 |
Akorn, Inc. and Hameln Pharmaceuticals gmbh Announce the Signing of the Exclusive License and Supply Agreement for two Orphan Drug NDA's: Calcium-DTPA and Zinc-DTPA |
|
| 10.26.2004 |
Akorn, Inc. Reports Net Sales of $15.4 Million in 2004 Third Quarter with Gross Margin of 44%, Net Income of $2.6 Million, and EBITDA of $2.9 Million |
|
| 10.20.2004 |
Akorn, Inc. and Hameln Pharmaceuticals gmbh Announce the Signing of an Exclusive Binding Term Sheet to License and Supply to Akorn two Orphan Drug NDA's: Calcium-DTPA and Zinc-DTPA. |
|
| 10.15.2004 |
Akorn, Inc. and Serum Institute of India, Ltd. Announce the Signing of an Exclusive Drug Development and Distribution Agreement for Oncology and Other Injectable Products |
|
| 10.13.2004 |
Akorn, Inc. to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference |
|
| 10.6.2004 |
Akorn, Inc. Responds to Event of Default - No Financial Impact |
|
| 9.22.2004 |
Akorn, Inc. and Strides Arcolab Limited Announce the Signing of a Definitive Agreement to Enter into a Joint Venture |
|
| 9.7.2004 |
Akorn, Inc. Names Marshall L. Goodwin as Vice President, Global Quality and Regulatory Compliance |
|
| 8.31.2004 |
Akorn, Inc. Enters Into An Option Agreement to License a Patent From The University of Texas M.D. Anderson Cancer Center |
|
| 8.27.2004 |
Arbitrator Resolves Dispute Between Akorn, Inc. and AEG Partners LLC |
|
| 8.24.2004 |
Akorn, Inc. Completes $14.1 Million Private Placement of Series B 6% Participating Convertible Preferred Stock |
|
| 8.18.2004 |
Akorn, Inc. Announces $14.1 Million Private Placement of Series B 6% Participating Convertible Preferred Stock |
|
| 8.13.2004 |
Akorn Reports Second Quarter 2004 Results |
|
| 7.21.2004 |
Akorn, Inc. and FDC Limited Announce Signing of Purchase and Supply Agreement |
|
| 6.17.2004 |
Akorn, Inc. Names Jeffrey A. Whitnell as Vice President, Finance and Chief Financial Officer |
|
| 5.24.2004 |
Akorn, Inc. to Present at Friedman Billings Ramsey 8th Annual Growth Investor Conference |
|
| 5.6.2004 |
Akorn and Aero Pharmaceuticals, Inc. Enter Development and Manufacturing Agreement |
|
| 5.3.2004 |
Akorn, Inc. Listed on OTC Bulletin Board |
|
| 4.21.2004 |
Akorn, Inc. and Strides Arcolab Limited Announce the Signing of a Memo of Understanding to Market Generic Drug Products in the U.S. Hospital Market |
|
| 2.9.2004 |
Akorn Receives Approval for Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment USP |
|
| 11.20.2003 |
Akorn, Inc. Announces the Election of Three New Directors |
|
| 10.9.2003 |
Akorn, Inc. Completes $40.5 Million Financing |
|
| 9.30.2003 |
Akorn, Inc. Settles SEC Matter |
|
| 9.25.2003 |
Akorn Signs Preferred Stock and Note Purchase Agreement With Investors for $40.5 Million in New Capital |
|
| 7.3.2003 |
Akorn Updates Status of Forbearance Agreement |
|
| 6.9.2003 |
Akorn Elects Arthur S. Przybyl as Chief Executive Officer |
|
| 2.18.2003 |
Akorn Receives Approval for Lidocaine Jelly, 2%; Arthur S. Przybyl Appointed Interim CEO |
|
